Literature DB >> 24942375

Development and psychometric evaluation of the urgency questionnaire for evaluating severity and health-related quality of life impact of urinary urgency in overactive bladder.

Karin S Coyne1, Chris C Sexton, Christine Thompson, Tamara Bavendam, Linda Brubaker.   

Abstract

INTRODUCTION AND HYPOTHESIS: Urinary urgency is the cardinal symptom of overactive bladder (OAB). However, there is no single instrument that assesses the context, severity, intensity, and daily life impact of urinary urgency. The purpose of this manuscript is to describe the methods and results of the qualitative and quantitative research conducted to develop a new tool for this purpose, the Urgency Questionnaire (UQ).
METHODS: Qualitative data from interviews with patients with urinary urgency were used to develop and refine the items and response options of the UQ. Three studies were used to evaluate psychometric properties: a clinical trial of tolterodine (Detrol; n = 974); a psychometric validation study (n = 163); and a test-retest validation study (n = 47). Item and exploratory factor analysis (EFA) were performed to assess the subscale structure, and the psychometric performance of the resulting scales was evaluated.
RESULTS: Fifteen Likert-scale items and four VAS questions were retained. A four-factor solution was shown to best fit the data, with the subscales: Impact on Daily Activities, Time to Control Urgency, Nocturia, and Fear of Incontinence. All subscales and VAS items demonstrated good reliability (Cronbach's α 0.79-0.94), convergent and discriminant validity, and responsiveness to change. The UQ differentiated between OAB patients and controls.
CONCLUSION: The results provide quantitative evidence that urinary urgency, as assessed by the UQ, is a pathological sensation distinctive from the normal urge to void and suggest that the UQ might be a reliable, valid, and responsive instrument for evaluating the severity and HRQL impact of urinary urgency in OAB.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24942375     DOI: 10.1007/s00192-014-2435-5

Source DB:  PubMed          Journal:  Int Urogynecol J        ISSN: 0937-3462            Impact factor:   2.894


  26 in total

1.  Urgency as the cardinal symptom of overactive bladder: a critical analysis.

Authors:  Linda Cardozo; Chris Chapple; Alan Wein
Journal:  World J Urol       Date:  2009-11-15       Impact factor: 4.226

2.  Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study.

Authors:  Debra E Irwin; Ian Milsom; Steinar Hunskaar; Kate Reilly; Zoe Kopp; Sender Herschorn; Karin Coyne; Con Kelleher; Christian Hampel; Walter Artibani; Paul Abrams
Journal:  Eur Urol       Date:  2006-10-02       Impact factor: 20.096

3.  Reliability and responsiveness of the Urgency Severity and Life Impact Questionnaire (USIQ).

Authors:  Lior Lowenstein; Leslie Rickey; Kimberly Kenton; Mary P Fitzgerald; Linda Brubaker; Mary Tulke; Joye Fordham; Elizabeth R Mueller
Journal:  Int Urogynecol J       Date:  2011-08-18       Impact factor: 2.894

Review 4.  The role of urinary urgency and its measurement in the overactive bladder symptom syndrome: current concepts and future prospects.

Authors:  Christopher R Chapple; Walter Artibani; Linda D Cardozo; David Castro-Diaz; Michael Craggs; Francois Haab; Vik Khullar; Eboo Versi
Journal:  BJU Int       Date:  2005-02       Impact factor: 5.588

Review 5.  Defining overactive bladder: epidemiology and burden of disease.

Authors:  Andrea Tubaro
Journal:  Urology       Date:  2004-12       Impact factor: 2.649

6.  Test-retest reliability of four questionnaires for patients with overactive bladder: the overactive bladder questionnaire (OAB-q), patient perception of bladder condition (PPBC), urgency questionnaire (UQ), and the primary OAB symptom questionnaire (POSQ).

Authors:  Louis S Matza; Christine L Thompson; Joel Krasnow; Jessica Brewster-Jordan; Teresa Zyczynski; Karin S Coyne
Journal:  Neurourol Urodyn       Date:  2005       Impact factor: 2.696

7.  The prevalence of lower urinary tract symptoms (LUTS) and overactive bladder (OAB) by racial/ethnic group and age: results from OAB-POLL.

Authors:  Karin S Coyne; Chris C Sexton; Jill A Bell; Christine L Thompson; Roger Dmochowski; Tamara Bavendam; Chieh-I Chen; J Quentin Clemens
Journal:  Neurourol Urodyn       Date:  2012-07-27       Impact factor: 2.696

8.  Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q.

Authors:  K Coyne; D Revicki; T Hunt; R Corey; W Stewart; J Bentkover; H Kurth; P Abrams
Journal:  Qual Life Res       Date:  2002-09       Impact factor: 4.147

9.  Prevalence and burden of overactive bladder in the United States.

Authors:  W F Stewart; J B Van Rooyen; G W Cundiff; P Abrams; A R Herzog; R Corey; T L Hunt; A J Wein
Journal:  World J Urol       Date:  2002-11-15       Impact factor: 4.226

10.  It's just the worry about not being able to control it! A qualitative study of living with overactive bladder.

Authors:  Paula Nicolson; Zoe Kopp; C R Chapple; C Kelleher
Journal:  Br J Health Psychol       Date:  2007-03-07
View more
  3 in total

1.  Effect of electroacupuncture versus solifenacin for moderate and severe overactive bladder: a multi-centre, randomized controlled trial study protocol.

Authors:  Qian Wen; Ning Li; Xueling Wang; Hao Li; Fengwei Tian; Weiwei Chen; Yanyan Lu; Zhishun Liu
Journal:  BMC Complement Med Ther       Date:  2020-07-16

2.  Validation of the urgency questionnaire in Portuguese: A new instrument to assess overactive bladder syndrome.

Authors:  Rodolfo Pacheco de Moraes; Jonas Lopes da Silva; Adriano Almeida Calado; Geraldo de Aguiar Cavalcanti
Journal:  Int Braz J Urol       Date:  2018 Mar-Apr       Impact factor: 1.541

3.  A meta-ethnography to understand the experience of living with urinary incontinence: 'is it just part and parcel of life?'

Authors:  Francine Toye; Karen L Barker
Journal:  BMC Urol       Date:  2020-01-16       Impact factor: 2.264

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.